Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life

Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life

<b>Background</b>. Several drugs which are easy to administer in outpatient settings have been authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to prevent hospital admission and death, complementing COVID-19 vaccines. However, the evidence on the efficac...

Full description

Bibliographic Details
Main Authors: Luca Cegolon, Riccardo Pol, Omar Simonetti, Francesca Larese Filon, Roberto Luzzati
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Pharmaceuticals
Subjects:
SARS-CoV-2
COVID-19
high-risk patients
antivirals
monoclonal antibodies
Sotrovimab
Online Access:https://www.mdpi.com/1424-8247/16/5/721

Similar Items

Similar Items